Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Coya Therapeutics, maintaining a price target of $14.
October 30, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Coya Therapeutics, maintaining a price target of $14.
The reaffirmation of a Buy rating and a maintained price target of $14 by Chardan Capital is a positive signal for investors, suggesting confidence in Coya Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100